Menu

APRIORI

Statement APRIORI

  • The overarching objective of APRIORI is to establish the Kilimanjaro Clinical Research Centre (KCRC), where multidisciplinary research will be conducted on prevention, control and treatment of malaria, tuberculosis and HIV/AIDS.
  • APRIORI’s guiding principles include: capacity building, multidisciplinary approach, equal partnership, open communication, long-term commitment, and sustainability.

 

Our priorities

Two focal areas have been identified:

  • rationale vaccine development and down-stream selection of vaccine candidates based on safety profile, analysis of immune response and efficacy
  • in-depth pharmacological studies to optimise treatment protocols for TB and for HIV-Tb concurrent treatment. 

All initiatives are geared towards building research and quality care capacity within a Tanzanian-owned institution.


Expertise from different areas

  • Capacity development comprises intensive south-south collaboration with selected African centres of excellence and north-south collaboration with European centres of excellence.

 

The African partners and expertise

  • Malaria Research & Training Centre (MRTC) , University of Bamako, Mali: Expertise on drugs trials and malaria vaccine testing; FDA compliant. Training programs.
  • Armauer Hansen Research Institute ( AHRI) , Ethiopia: TB expertise on diagnosis, treatment and vaccine testing.

 

The Dutch partners and expertise

  • Radboud University Nijmegen: Malaria Vaccine, host defense, public health, management, tuberculosis, pharmacology TB and HIV medication.
  • Rijksinstitituut voor Volksgezondheid en Milieu (RIVM): National mycobacterial reference laboratory; identification, drug susceptibility of mycobacteria, molecular epidemiology of tuberculosis.
  • Leiden University: Immungenetics and host defence to tuberculosis, cytokines vaccination.
  • Maastricht University: Behavioral prevention science / Health promotion.
  • Wageningen University: Human nutrition and immunology
  • Erasmus MC Rotterdam: Public health, mathematical modeling
  • Dekkerswald Nijmegen: National TB reference hospital
  • KNCV Tuberculosis Foundation: Site preparation for vaccine studies, drug effectiveness studies, use surveillance data, training programs

 

The European partners and expertise

  • London School of Hygiene and Tropical Medicine, UK: malaria and tuberculosis epidemiology/pathophysiology/immunology and drug trails
  • University of Copenhagen, Denmark: malaria and tuberculosis epidemioloy/pathophysiology/immunology and drug trials
  • Statens Serum Institutes, Denmark: TB vaccines discovery, development and testing.